Type 1 diabetes mellitus Nutritional, Metabolic, Endocrine Type 1 diabetes mellitus
Conditions
Interventions
Demographic, clinical and routine laboratory data are collected via interview with participants and from their medical records at a single study visit. An optional blood sample is collected for the me
Sponsors
Imperial College of Science, Technology and Medicine
Eligibility
Sex/Gender
All
Age
1 Years to 100 Years
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 29/08/2024: 1. Age =1 years 2. Male or female 3. Clinical diagnosis of type 1 diabetes or unclassified but possible type 1 diabetes and have been diagnosed less than 6 months at the time of recruitment or the sibling of someone meeting the criteria above who has consented to the study. Sibling must be free from diabetes Previous inclusion criteria: 1. Age =5 years 2. Male or female 3. Clinical diagnosis of type 1 diabetes or unclassified but possible type 1 diabetes and have been diagnosed less than 6 months at the time of recruitment or the sibling of someone meeting the criteria above who has consented to the study. Sibling must be free from diabetes
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 29/08/2024: 1. Children under 1 years of age 2. Individuals aged 16 years or older who are not competent to give consent 3. Recently diagnosed type 1 diabetes participants, who have been previously diagnosed with type 2 diabetes, unless the initial diagnosis of type 2 diabetes is also within 6 months prior to enrolment Previous exclusion criteria: 1. Children under 5 years of age. 2. Individuals aged 16 years or older who are not competent to give consent. 3. Recently diagnosed type 1 diabetes participants, who have been previously diagnosed with type 2 diabetes, unless the initial diagnosis of type 2 diabetes is also within 6 months prior to enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Autoantibody status is measured in a single laboratory using established radiobinding assays at baseline and characteristics at presentation are measured using patient interviews, medical records and pathology systems at baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures. | — |
Countries
England, Northern Ireland, Scotland, United Kingdom, Wales
Outcome results
None listed